Fintel reports that on December 8, 2023, Baird initiated coverage of Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform recommendation.
Analyst Price Forecast Suggests 38.45% Upside
As of November 27, 2023, the average one-year price target for Xenon Pharmaceuticals is 53.08. The forecasts range from a low of 46.46 to a high of $63.00. The average price target represents an increase of 38.45% from its latest reported closing price of 38.34.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Xenon Pharmaceuticals is 10MM, an increase of ∞%. The projected annual non-GAAP EPS is -2.88.
What is the Fund Sentiment?
There are 312 funds or institutions reporting positions in Xenon Pharmaceuticals. This is an increase of 30 owner(s) or 10.64% in the last quarter. Average portfolio weight of all funds dedicated to XENE is 0.39%, a decrease of 12.19%. Total shares owned by institutions increased in the last three months by 2.77% to 74,166K shares. 
The put/call ratio of XENE is 1.00, indicating a bearish outlook.
What are Other Shareholders Doing?
Avoro Capital Advisors holds 4,900K shares representing 6.51% ownership of the company. No change in the last quarter.
SMCWX - SMALLCAP WORLD FUND INC holds 4,721K shares representing 6.27% ownership of the company. In it's prior filing, the firm reported owning 4,596K shares, representing an increase of 2.64%. The firm decreased its portfolio allocation in XENE by 3.74% over the last quarter.
Driehaus Capital Management holds 4,513K shares representing 6.00% ownership of the company. In it's prior filing, the firm reported owning 4,761K shares, representing a decrease of 5.49%. The firm decreased its portfolio allocation in XENE by 13.40% over the last quarter.
Polar Capital Holdings holds 3,004K shares representing 3.99% ownership of the company. In it's prior filing, the firm reported owning 3,022K shares, representing a decrease of 0.61%. The firm decreased its portfolio allocation in XENE by 5.25% over the last quarter.
Capital International Investors holds 2,447K shares representing 3.25% ownership of the company. In it's prior filing, the firm reported owning 2,322K shares, representing an increase of 5.10%. The firm decreased its portfolio allocation in XENE by 1.68% over the last quarter.
Xenon Pharmaceuticals Background Information
(This description is provided by the company.)
Xenon is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. The Company is advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
